A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System

NCT00678171 | Completed

• 1 other identifier: 06-TLF-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 10

Brief Summary

This study will explore the use of recombinant OP-1 in conjunction with surgical treatment of single-level TLIF of the lumbar spine.

Conditions

Degenerative Disc Disease

Keywords

Degenerative Disc Disease

Outcome Measures

Primary Outcomes (1)

• Pain and function as measured by an Oswestry Disability Index, no revisions, removals or supplemental fixations, fusion success, defined as radiographic evidence of fusion, maintenance or improvement in lower extremity neurologic function

  12 and 24 months post intervention

Secondary Outcomes (1)

• Quality of life determinations (SF-36), pain assessments (VAS), work status and assessment of additional radiographic parameters

  12 and 24 months post intervention

Study Arms (2)

OP-1 Putty

EXPERIMENTAL

Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.

Device: TLIF with a PEEK Spacer System and XIA Spinal System

Autograft

ACTIVE COMPARATOR

Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.

Device: TLIF with a PEEK Spacer System and XIA Spinal System

Interventions

TLIF with a PEEK Spacer System and XIA Spinal System DEVICE

TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.

Also known as: TLIF with a Spacer System

Autograft; OP-1 Putty

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient is willing and able to understand, sign and date the study-specific, Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved patient informed consent and applicable privacy regulations.
• The patient has a documented diagnosis of DDD with up to Grade I spondylolisthesis demonstrated by radiographic imaging (by plain film/discography within 12 weeks of surgery and/or computed tomography (CT scan/magnetic resonance imaging \[MRI\].
• The patient requires single level lumbar fusion (L2 to S1)

You may not qualify if:

• The patient has a history of previous surgery in the lumbar spine with or without attempted fusion {Note: a history of lumbar decompression surgery is permitted}.
• The patient has Grade II, Grade III or Grade IV spondylolisthesis.
• The patient has gross spinal instability measured on flexion/extension radiographs of \>25% translation of the vertebrae, or ≥20 degrees of angular motion or has significant (\>10%) scoliosis.
• The patient is receiving treatment (before, during or after surgery) with a drug that interferes with bone metabolism or is being treated with a bone growth stimulator.
• The patient has been treated in the last 6 months with radiation, chemotherapy, immunosuppression or systemic corticosteroids.
• The patient has a history of, or has any malignancy or spinal tumor of any type, with the exception of a history of a treated basal or squamous cell carcinoma.
• The patient is morbidly obese (defined as body mass index \[BMI\] \> 35).
• The patient currently uses tobacco products, within 3 weeks prior to time of treatment.
• The patient is known to require at the time of treatment, additional surgery to the lumbar spinal region within the next 6 months or has symptomatic multilevel degenerative disease requiring possible instrumented fusion of more than one level.
• The patient has previously been treated with or exposed to any Bone Morphogenetic Proteins (BMPs).
• The patient is contraindicated for iliac crest autografting in that the Investigator believes the patient would be unable to provide sufficient quantity or adequate quality autograft (e.g., osteoporosis as defined by this protocol) from a unilateral iliac crest harvest.
• The patient has a previous diagnosis of Paget's disease, osteomalacia or any other endocrine or metabolic bone disease that affects osteogenesis.
• The patient has a documented history of osteoporosis or has a risk of osteoporosis as defined by an Osteoporosis Risk Assessment Instrument (ORAI) score of ≥ 9 and a DEXA Scan T score of ≥-2.5 standard deviations below the normal range within one year of enrollment.

Sponsors & Collaborators

• Olympus Biotech Corporation: lead

Study Sites (10)

Unknown Facility

Los Angeles, California, 90048, United States

Location

Unknown Facility

San Diego, California, 92103, United States

Location

Unknown Facility

Durango, Colorado, 81301, United States

Location

Unknown Facility

Boston, Massachusetts, 02120, United States

Location

Unknown Facility

Southfield, Michigan, 48034, United States

Location

Unknown Facility

Minneapolis, Minnesota, 55404, United States

Location

Unknown Facility

Omaha, Nebraska, 68154, United States

Location

Unknown Facility

Charlotte, North Carolina, 28207, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19152, United States

Location

Unknown Facility

Temple, Texas, 76508, United States

Location

MeSH Terms

Conditions

Intervertebral Disc Degeneration

Condition Hierarchy (Ancestors)

Spinal Diseases; Bone Diseases; Musculoskeletal Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 13, 2008
• First Posted: May 15, 2008
• Study Start: February 1, 2007
• Primary Completion: March 1, 2008
• Study Completion: March 1, 2010
• Last Updated: February 5, 2014

Record last verified: 2014-01

Locations

US (10)